Atypical hemolytic uremic syndrome often progresses to end-stage renal disease and recurs after kidney transplantation, even with empiric plasma therapy. Guidelines on the treatment of this devastating disease have now been published, following a consensus conference in Bergamo, Italy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Loirat, C., Noris, M. & Fremeaux-Bacchi, V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 23, 1957–1972 (2008).
Caprioli, J. et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267–1279 (2006).
Bresin, E. et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic syndrome: prognostic significance of genetic background. Clin. J. Am. Soc. Nephrol. 1, 88–89 (2006).
Saland, J. M. et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am. J. Transplant. 6, 1948–1952 (2006).
Saland, J. M., Ruggenenti, P., Remuzzi, G. & the Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 20, 940–949 (2009).
Saland, J. M. et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4, 201–206 (2009).
Dragon-Durey, M. et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555–563 (2005).
Nürnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542–544 (2009).
Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544–546 (2009).
Mache, C. J. et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. doi:10.2215/CJN.01090209.
Acknowledgements
The author's work is supported by a grant (A080588) from the Korea Healthcare technology R&D Project, Ministry for Health, welfare and Family Affairs, Republic of Korea.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Cheong, H. Can liver–kidney transplantation cure aHUS?. Nat Rev Nephrol 5, 556–557 (2009). https://doi.org/10.1038/nrneph.2009.148
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.148
